Targeted therapy for malignant gliomas.
The identification of markers that are associated with tumour but not normal tissue has allowed the development of highly-specific targeted therapies. Monoclonal antibodies, either alone or linked to radioisotopes or toxins, have provided a powerful tool for research, as well as the basis for promising therapeutic agents with less side effects than standard radiotherapy or chemotherapy. A new class of drugs, the tyrosine kinase inhibitors, which interfere with the function of key molecules in cancer-promoting pathways, have had a dramatic effect in haematological malignancy and are being trialled in solid tumours, including glioma. Although the problem of achieving specific, high-level delivery of these various agents to tumours in the brain remains a major issue, encouraging early results with some targeted agents support the attractive theoretical principles of this new paradigm. Further work to identify new molecular targets and to develop agents exploiting them, is needed, as well as confirmation of their safety and efficacy by clinical trials.
Morokoff
Andrew P
AP
Department of Surgery, Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia. a_morokoff@hotmail.com
Novak
Ulrike
U
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000276:immunology; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005910:Glioma / Q000628:therapy*; D006801:Humans; D008954:Models, Biological; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D004791:Enzyme Inhibitors; D011505:Protein-Tyrosine Kinases